Skip to main content
Delfa

← Trials/Trial dossier/NCT01312363

X-MEN

Completed

Study for the Tolerability of Exelon Patch (Rivastigmine) for Alzheimer's Disease (AD) Patients

A Six-month, Open Labeled, Multi-centered, Observational Study for the Tolerability of Exelon Patch (Rivastigmine) for Patients With Alzheimer's Disease

Asset

Rivastigmine

Listed sites

19

Recruiting sites

-

Enrollment

300

actual

Study population

Alzheimer’s disease

Key I/E criterion

•Alzheimer's disease

Primary endpoint

•Adverse events

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT01312363
Org study IDX-MEN

Timeline

Milestones

Study start2009-06 (month precision)
Study first posted2011-03-10estimated
Primary completion2011-06actual (month precision)
Study completion2011-07actual (month precision)
Last update posted2016-05-04estimated

Assets

Drug assets

Rivastigmine

Study populations

Who this study enrolls

Alzheimer’s disease

Eligibility

Who can enroll

Minimum age51 Years
Maximum age85 Years
SexAll
Healthy volunteersNot accepted

Inclusion criteria

•Probable AD by NINCDS-ADRDA and DSM-IV
•Male and female aged from 51 to 85 years old
•Magnetic resonance imaging or computed tomographic scan within 12 months consistent with a diagnosis of probable AD
•Patients who approved to release of personal information

Exclusion criteria

•Patient with any active pulmonary, gastrointestinal, renal, hepatic (severe hepatic function impaired patients), endocrine, or cardiovascular disease, clinically significant laboratory abnormalities, or any medical condition which would prohibit them from completing the study
•Any patients suspicious of drug addiction or alcohol addiction for the past 10 years
•Any other patients to be decided to be inappropriate for the study by the investigators

Endpoints (2)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Safety / tolerability / PK
1
Other (unclassified)
1

Safety / tolerability / PK

1 endpoint
Primary/protocol endpoint

Number of participants with adverse events

Time frame:24 weeks

event count, event

Other (unclassified)

1 endpoint
Secondary/protocol endpoint/low confidence

Factors for the disuse of Rivastigmine patch

Time frame:24 weeks

descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 21, 2026
Endpoint classificationDelfa ADRD endpoint taxonomy
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 21, 2026 snapshot.